Home / KEEP BUT DO NOT DISPLAY / Alerts / FDA Approves Johnson & Johnson’s First In Class SGLT-2 Inhibitor Diabetes Drug, Canagliflozin

FDA Approves Johnson & Johnson’s First In Class SGLT-2 Inhibitor Diabetes Drug, Canagliflozin

Mar 28, 2013
1,459 views

FDA Approves Johnson & Johnson’s First In Class SGLT-2 Inhibitor diabetes drug, canagliflozin (Invokana). See this week’s Item #1.

J&J Recalls 2 Million Blood Glucose Meters. See this week’s Item #5.